Literature DB >> 22419483

Two novel patients with Bohring-Opitz syndrome caused by de novo ASXL1 mutations.

Pamela Magini1, Matteo Della Monica, Maria Luisa Giovannucci Uzielli, Patrizia Mongelli, Gloria Scarselli, Eleonora Gambineri, Gioacchino Scarano, Marco Seri.   

Abstract

Bohring-Opitz syndrome (BOS) is a rare condition characterized by facial anomalies, multiple malformations, failure to thrive and severe intellectual disabilities. Recently, the cause was identified on the basis of de novo heterozygous mutations in the ASXL1 gene. We report on two novel cases carrying two previously undescribed mutations (c.2407_2411del5 [p.Q803TfsX17] and c.2893C>T [p.R965X]). These new data further support ASXL1 as cause of BOS and may contribute to a more precise definition of the phenotype caused by the disruption of this gene.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22419483     DOI: 10.1002/ajmg.a.35265

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  18 in total

1.  Clinical management of patients with ASXL1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance.

Authors:  Bianca Russell; Jennifer J Johnston; Leslie G Biesecker; Nancy Kramer; Angela Pickart; William Rhead; Wen-Hann Tan; Catherine A Brownstein; L Kate Clarkson; Amy Dobson; Avi Z Rosenberg; Samantha A Schrier Vergano; Benjamin M Helm; Rachel E Harrison; John M Graham
Journal:  Am J Med Genet A       Date:  2015-04-29       Impact factor: 2.802

Review 2.  Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz Syndrome.

Authors:  Colleen M Carlston; Anne H O'Donnell-Luria; Hunter R Underhill; Beryl B Cummings; Ben Weisburd; Eric V Minikel; Daniel P Birnbaum; Tatiana Tvrdik; Daniel G MacArthur; Rong Mao
Journal:  Hum Mutat       Date:  2017-03-21       Impact factor: 4.878

Review 3.  The Role of Additional Sex Combs-Like Proteins in Cancer.

Authors:  Jean-Baptiste Micol; Omar Abdel-Wahab
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

4.  Familial hematological malignancies: ASXL1 gene investigation.

Authors:  W S Hamadou; R E Abed; S Besbes; V Bourdon; A Fabre; Y B Youssef; M A Laatiri; F Eisinger; V Mari; P Gesta; H Dreyfus; V Bonadona; C Dugast; H Zattara; L Faivre; S Y Jemni; T Noguchi; A Khélif; H Sobol; Z Soua
Journal:  Clin Transl Oncol       Date:  2015-08-19       Impact factor: 3.405

5.  A de novo truncating mutation in ASXL1 associated with segmental overgrowth.

Authors:  Stephanie Efthymiou; Vincenzo Salpietro; Erica Pironti; Maria Bonsignore; Valentina Ferrazzoli; Gabriella Di Rosa; Henry Houlden
Journal:  J Genet       Date:  2019-12       Impact factor: 1.166

6.  Understanding the phenotypic spectrum of ASXL-related disease: Ten cases and a review of the literature.

Authors:  Vishnu Anand Cuddapah; Holly A Dubbs; Laura Adang; Steven L Kugler; Elizabeth M McCormick; Zarazuela Zolkipli-Cunningham; Xilma R Ortiz-González; Shana McCormack; Elaine Zackai; Daniel J Licht; Marni J Falk; Eric D Marsh
Journal:  Am J Med Genet A       Date:  2021-03-10       Impact factor: 2.578

7.  Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.

Authors:  Anand Balasubramani; Antti Larjo; Jed A Bassein; Xing Chang; Ryan B Hastie; Susan M Togher; Harri Lähdesmäki; Anjana Rao
Journal:  Nat Commun       Date:  2015-06-22       Impact factor: 14.919

8.  Expanding our knowledge of conditions associated with the ASXL gene family.

Authors:  Bianca Russell; John M Graham
Journal:  Genome Med       Date:  2013-02-21       Impact factor: 11.117

9.  De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome.

Authors:  Matthew N Bainbridge; Hao Hu; Donna M Muzny; Luciana Musante; James R Lupski; Brett H Graham; Wei Chen; Karen W Gripp; Kim Jenny; Thomas F Wienker; Yaping Yang; V Reid Sutton; Richard A Gibbs; H Hilger Ropers
Journal:  Genome Med       Date:  2013-02-05       Impact factor: 11.117

10.  Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.

Authors:  Omar Abdel-Wahab; Jie Gao; Mazhar Adli; Anwesha Dey; Thomas Trimarchi; Young Rock Chung; Cem Kuscu; Todd Hricik; Delphine Ndiaye-Lobry; Lindsay M Lafave; Richard Koche; Alan H Shih; Olga A Guryanova; Eunhee Kim; Sheng Li; Suveg Pandey; Joseph Y Shin; Leon Telis; Jinfeng Liu; Parva K Bhatt; Sebastien Monette; Xinyang Zhao; Christopher E Mason; Christopher Y Park; Bradley E Bernstein; Iannis Aifantis; Ross L Levine
Journal:  J Exp Med       Date:  2013-11-11       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.